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Depression is a common mental disorder that co-occurs in other neurological and somatic diseases. Further, sex
differences exist in the prevalence rates of many of these diseases, as well as within non-disease associated
depression. In this review, the case is made for needing a better recognition of the source of the symptoms of
depression with respect to the sex of the individual; in that, some disease states, which includes the
neuroendocrine and immune reactions to the underlying pathophysiology of the disease, may initiate depressive
symptoms more often in one sex over the other. The diseases specifically addressed to make this argument are:
epilepsy, Alzheimer’s disease, cancer, and cardiovascular disease. For each of these conditions, a review of the
following are presented: prevalence rates of the conditions within each sex, prevalence rates of depressive
symptoms within the conditions, identified relationships to gonadal hormones, and possible interactions between
gonadal hormones, adrenal hormones, and immune signaling. Conclusions are drawn suggesting that an evaluation
of the root causes for depressive symptoms in patients with these conditions is necessary, as the underlying
mechanisms for eliciting the depressive symptoms may be qualitatively different across the four diseases discussed.
This review attempts to identify and understand the mechanisms of depression associated with these diseases, in
the context of the known sex differences in the disease prevalence and its age of onset. Hence, more extensive,
sex-specific model systems are warranted that utilize these disease states to elicit depressive symptoms in order to
create more focused, efficient, and sex-specific treatments for patients suffering from these diseases and concurrent
depressive symptoms.
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Depression is the leading cause of disability in the
United States for individuals 15–44 years of age [1]. In
addition, depression is predictive of suicide [2], and
suicide accounts for more deaths each year than auto
accidents [3]. Despite the high incidence of depression
and the increased risk of death in depressed individuals,
our understanding of the causes of depression is in-
complete, limiting the efficacy of available treatments.
A more complete appreciation for the range of possible
neural substrates that underlie depression may improve
our understanding and thereby our treatment of the
disorder. Although the phenotype of depression is* Correspondence: gmccand@emory.edu
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reproduction in any medium, provided the orsomewhat consistent, the mechanisms that account for
the manifestation of that phenotype are varied. By
analogy, one could travel from North America to Australia
by many different routes and by many different methods,
but once the journey was complete, the view upon
arrival would be the same. In the case of depression,
the mechanisms that mediate depression in a young
woman with a history of chronic abuse and a recent
psychological trauma, are likely to differ from the
mechanisms mediating depression in an elderly man
who recently had a stroke but who has no history of
trauma or abuse. While the mechanisms mediating the
depression may differ, the core mental and behavioral
symptoms for these two individuals could be nearly
identical. Two of the most obvious trends that suggest
that depression is not a singular entity are the pervasive
sex difference in the incidence of depression and the
interactions among depression and diseases.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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depression compared to men [4,5] and though it is well
established that the prevalence, incidence, and morbidity
risk for females is greater throughout life, the underlying
mechanisms of this sex difference are relatively undefined.
Women experience a steep increase in rates of depression
beginning at mid-puberty [5,6]; similarly, women ex-
perience fluctuations of sex steroids and corresponding
vulnerabilities to mood disorders during and after
pregnancy and again at menopause [4]. The pattern of
hormonal change parallel to the biological susceptibility to
the development of mood disorders in females paints a
dramatic role for sex steroids in depression. Despite
this relationship, other variables implicated in the
pathogenesis of depression, including inflammation [7],
socio-demographic demands [5], and a multi-factorial
genetic predisposition [4], likely interact with sex ste-
roids to influence specific disease manifestation across
individuals. Further highlighting the role of sex steroids
in disease, several common medical disorders are
exacerbated by hormonal changes associated with
the menstrual cycle [8], vulnerabilities that are thought to
be related to estrogen’s interactions with both the immune
and neuroendocrine systems.
Both neural (e.g. epilepsy [9] and Alzheimer’s disease [10])
and somatic disease (e.g. cancer [11] and cardiovascular
disease [12]) are accompanied by a greater prevalence
of comorbid mood disorders (see Table 1). The lifetime
prevalence of depression among those diagnosed with
epilepsy may be as high as 55% depending on the type
and severity of epilepsy [9,13]. Pre-existing depression
among patients with new-onset epilepsy is up to seven
times more common than in a control population
(reviewed in Kanner [14]). Depressive episodes in life
confer an increased risk of developing dementia or
Alzheimer’s disease later in life, while depression is
prevalent in 35-50% of patients already diagnosed with
Alzheimer’s disease [10]. Among cancer patients, theTable 1 Depression in disease states: sex differences
Disease Baseline sex difference Comorbid d









Type dependent: Liver: M > F
Lung: M > F (but F > M given
same risk factors) Thyroid: F > M
Up to 40%, depen
cancer and severit
Cardiovascular disease
Age dependent: M > F younger
than 45; F > M older than 45
15-20%; 1/3 of s
bidirectiprevalence of major depression can be greater than
40% depending on the method of diagnosis and type of
cancer [11]. Similarly, the prevalence of major depression
among cardiac patients is three-fold higher than that
observed in the general population [12], and, indicating
the bidirectionality of the comorbidity, patients with
depression are at a greater risk for a cardiac event in a
dose–response manner.
From a distance, the interaction between disease and
depressive disorders confers no pattern of protection or
susceptibility in terms of sex steroids; rather, the unique
properties of the disease states in conjunction with sex
steroids interact to modulate disease symptomology,
progression, and mortality. In this review, we will discuss
how sex differences observed within depressive disorders
vary in the context of concomitant disease and explore
how sex steroids may differentially modulate depression
within disease.
Depression and neural disease
Epilepsy, sex, and depression
Epilepsy, or chronically recurring unprovoked cortical
seizures, affects approximately two million Americans,
and about 140,000 new cases of epilepsy are diagnosed
in the United States each year [15]. Over two-thirds of
epileptic seizures begin in childhood, and incidence
levels in adulthood increase again beginning at age 60
[16]. According to a recent meta-analysis [17], females
may have a slightly lower susceptibility to epilepsy than
males (46.2 vs. 50.7 per 100,000), though the greater
incidence in men may be, in part, attributed to the higher
number of risk factors in men, including head injury and
stroke. When only idiopathic seizures were considered,
however, the sex difference remained [17].
The relationship between depression and epilepsy is
not new; Hippocrates himself has been attributed with
noting this bidirectionality: “Melancholics ordinarily
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F >M; approximately twice as high
in females or an equivalent ratio to
the baseline depressed population
[4,12,86,87,89,90]
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takes; if it bears upon the body, epilepsy, if upon the
intelligence, melancholy” (translated and cited in Kanner,
2003 and Mula, 2012[9,18]). The lifetime prevalence of
depression among those diagnosed with epilepsy is 6-55%
depending on the type and severity of epilepsy [9,13], and
the rate of suicide among epileptic patients may be five to
25 times higher than that of the general population [19]
(see Table 1). Conversely, a pre-existing diagnosis of
depression among patients with new-onset epilepsy is up
to seven times more common than in a control population
[14]. Left temporal lobe epilepsy is commonly associated
with the greatest propensity for depression [20-22];
however, some have argued that bilateral epilepsy may
be somewhat protective against depressive symptoms as
reported on the Beck Depressive Inventory [20] and others
have reported no difference in laterality and depression
[23]. Most depression characterized in epilepsy is interictal,
occurring between seizure bouts, though postictal de-
pression, defined explicitly as a depressive mood in the
72 hours following a seizure, has also been identified in
a large portion of epileptic patients [9].
Animal models recapitulate the increased susceptibility
to depressive-like behaviors in both status epilepticus
[24] and absence models [25,26] and may offer insight
into the mechanism underlying the association between
epilepsy and depression. Mazarati and colleagues [24]
showed increased immobility in the forced swim test
and decreased saccharin consumption after lithium and
pilocarpine-induced status epilepticus, coexisting with
decreased hippocampal serotonin and decreased seroto-
nergic release from the dorsal raphe, all indicative of a
depressive-like phenotype. Intriguingly, treatment with
the selective serotonin reuptake inhibitor, fluoxetine,
decreased brain excitability associated with status
epilepticus but did not alter performance in the forced
swim test [24]. Conversely, the genetically epilepsy
prone rat (GEPR) has been shown to be susceptible to
the proconvulsant activity of antidepressants, as have
cats and rabbits at supratherapeutic doses of these drugs
(reviewed in Jobe and Browning [27]). Moreover, the
WAG/Rij rat strain is used as a model of absence epilepsy
and shows increased immobility in the forced swim test
and decreased sucrose consumption, an effect that can
be blocked by treatment with the antiepileptic drug,
ethosuximide [28]. Russo and colleagues [29] sought to
determine if this simultaneously antidepressant and
anticonvulsant effect of ethosuximide, a purported
calcium channel inhibitor, was specific to that particular
drug, which is only effective in absence seizures. Their
study revealed that while levetiracetam and zonisamide,
other compounds that target calcium channels (but not
the sodium-channel targeting carbamezapine), lowered
the incidence of spike-wave discharges (SWDs), onlyethosuximide lowered SWDs and reduced depressive
behavior in the forced swim test [29]. Noradrenergic
and serotonergic deficits are believed to cause the seizure
predisposition in GEPR and other mammals, which may
be linked to depressive vulnerability [27]. Antidepressant
anticonvulsant activity may be mediated by the restoration
of these deficits; yet, simultaneously, antidepressants can
enhance glutamatergic activity and inhibit GABAergic
activity, which may lower seizure threshold [27]. These data
hint that while depression and epilepsy may share common
mechanisms, when combined, the neuropathology is more
complex than in a typical depressive pattern alone.
In spite of the two-fold greater prevalence of depression
in females in general, several studies have found an absence
of a consistent sex difference in epilepsy-associated depres-
sion [21,30]. In one large population-based study examining
nearly 37,000 people of which 0.6% were diagnosed with
epilepsy of heterogenous types, the odds ratio for anxiety
disorders or suicidal thoughts among epileptic patients
was 2.4 (95% Confidence interval = 1.5-3.8) and 2.2
(1.4-3.3), respectively [30]. Major depressive disorder
had a significant age by sex interaction, such that male
epileptic patients became more susceptible to depression
with age while women became less susceptible [30].
However, this study did not factor in the type of epilepsy,
and the greatest sex differences have been seen specifically
with left temporal lobe epilepsy (TLE; [20,22]). Left TLE
has been associated with a male-specific vulnerability to
depression [20,22] as well as more severe depressive
symptoms on the Beck Depressive Inventory [20]. This
data is particularly interesting, and relevant for clinicians,
given the dramatic suicide data among epileptics [19] and
the sex disparity in suicide [31]. Collectively, the clinical
data points toward a diminished if not altered sex difference
in epilepsy-associated depression.
What then causes this alteration of the typical sex
difference in depression when associated with epilepsy?
It is possible that females simply experience less severe
seizures on average. Both in humans and in animal
models, progesterone can be anticonvulsant and estrogen
proconvulsant, though rats typically experience reductions
in seizures during proestrus, when both hormones are at
their peak (reviewed in Frye [32]). Estrogen potentiates
non-NMDA glutamatergic transmission, but reduces
seizures associated with GABAA or NMDA activity
[32]. Progesterone’s effects are at least in part due to
actions by its metabolite, allopregnanolone, 3α-hydroxy-5α-
pregnan-20-one (3α,5α-THP), which is not affected by a
menopausal or menstrual state [32,33]. Allopregnanolone is
a powerful ligand for the GABAA/benzodiazepine receptor
complex, which may explain its importance in seizure
reduction [32]. Testosterone can provoke proconvulsant
activity; castration on the day of birth reduces susceptibility
to seizures in the substantia nigra pars reticulata [34], but
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[35]. It is possible that while females show a baseline
vulnerability to depression, they are somewhat protected
from the exacerbation of altered noradrenergic and
serotonergic signaling caused by seizure activity due to the
effects of ovarian hormones (or their metabolites). Males,
on the other hand, may show increased susceptibility,
ending up with a final erasure of the sex disparity in
depression when associated with epilepsy. This highlights
the important fact that depression is mediated by numerous
mechanisms – including neurochemical, hormonal,
and inflammatory pathways – that may be differentially
affected by sex and disease states.
Alzheimer’s disease, sex, and depression
Advanced age is the number one risk factor for developing
the spectrum of Alzheimer’s disease (AD) related patholo-
gies and risk increases with age [36-38]. Women are at a
greater risk of Alzheimer’s pathology [39], although men
carry a greater risk of death from the disease [36]. Clinical
and pre-clinical studies have shown that females carry an
increased risk of developing AD pathology compared to
males, even after controlling for increased life span [40,41].
The changing status of sex hormones in aging contributes
to the differential diagnoses and prognoses of men and
women, as the sudden loss of ovarian hormones following
menopause in women is attributed with the increased
prevalence of the disease and an observed greater de-
position of beta-amyloid (Aβ) plaques in the brains of
AD positive women [37]. Depression is diagnosed in
35-50% of Alzheimer’s patients [10], though depressive
symptoms are reported in up to 86% of patients [39]
(see Table 1). The co-expression of depression with AD
is associated with decreased quality of life, more severe
cognitive deficits, and decreased longevity [38,39,42]
though the diagnosis of depression with AD is a difficult
one to make [42]. Depression and AD share similar genetic
and environmental susceptibilities [10], which may speak to
the bidirectionality of disease expression, yet the underlying
mechanisms of the relationship are unclear. Mood distur-
bances, including depression, are reported to be three to
four times as prevalent among the AD population [42],
while similarly, a history of mood disorders increases the
risk of the development of AD [43]. One study evaluating
more than 1,300 patients over 14 years found depression to
be a significant risk factor for the development of AD in
men, but not women [10], which is an interesting finding in
light of the increased rates and pathological load of AD in
females. The exact interaction of AD pathology and sex
steroids is complex and not well understood, though a role
for sex steroids in the epidemiology and pathology of AD is
undeniable. Generally speaking, estrogens and androgens
are well recognized for their neuroprotective properties,
including involvement in promoting cell survival, neuronaldifferentiation, and reducing inflammation [37,44].
Compared to age-matched controls, reduced circulating
levels of 17 beta-estradiol and testosterone are observed
in female and male patients with AD, respectively
[37,44]. On a cellular level, decreased levels of sex
steroids correlate with the increased load of Aβ in both
sexes and the increased reactivity of estrogen receptors
in women [37]. Again indicative of the dense relationship
between the hypothalamic-pituitary-adrenal (HPA) and
hypothalamic-pituitary-gonadal (HPG) axes, the HPA
axis also alters the relationship between sex and AD.
AD patients are reported to exhibit a delayed cortisol
recovery following a stressor, and AD patients with
higher levels of cortisol perform worse on cognitive
tasks [45,46]. Alternatively, age-related mitochondrial
dysfunction and consequent increases in reactive oxy-
gen species have been proposed to contribute to the
neurodegeneration observed in AD [47].
Depression and somatic disease
As discussed above, diseases with direct effects on the
brain, such as Alzheimer’s disease, are well documented
to cause changes in mental status, including the onset of
depressive symptoms, as the disease progresses [48,49].
However, the link between neural diseases and depression
is more intuitive than those of non-neuronal diseases.
Regardless, connections between peripheral non-neuronal
diseases and brain-associated changes paralleling what is
observed in depressed subjects are still evident. These
studies have identified patient populations with conditions
such as peripheral cancers or cardiovascular disease, as
well as an incidence of depressive symptoms, and they have
then assessed the patient’s brains for neuronal markers of
depression. Thus, the changes in neurochemistry and
neuroanatomy identified in this way suggest a biological
link between these somatic diseases and the abnormal brain
activity thought to underlie symptoms of depression.
Cancer, sex, and depression
Cancer is the second leading cause of death in the
United States after heart disease, and kills more than
half a million Americans every year [50]. The top five
cancer sites differ in incidence and mortality between
men and women but show some overlap: the cancers
with the highest incidence in men are, in order, prostate,
lung, colorectal, bladder, and melanoma; and those with
the highest incidence in women are breast, lung, colorectal,
uterine, and thyroid [50]. Lung cancer kills the most men
and women each year, and colorectal cancer and pancreatic
cancer are also among the top five deadliest cancers for
both men and women [50].
Both the cancer disease and the treatments of that
disease are documented to cause significant changes in
neuroanatomy and neurochemistry. For instance, Cousins
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treatment for breast cancer caused a significant reduction
in neurotransmitter-related chemistry: myo-inositol,
choline and glutamate [51]. Another breast-cancer case
study found depressed activation of the anterior cingulate
cortex (subgenual cingulate cortex), which was subse-
quently elevated following behavioral therapy [52].
This provides evidence for both disease and disease-
treatment associated effects upon the brain that parallel
those observed in depression, and strengthens the proposed
association between the occurrence of peripheral cancers
and mood disorders.
Depression and cancer often co-exist, with major depres-
sion prevalence reportedly greater than 40% depending
on the method of diagnosis and type of cancer [11]
(see Table 1). Major depression is particularly highly
associated with oropharyngeal, pancreatic, breast, and
lung cancers, and the prevalence of depression increases
with disease severity and progression [11,53]. While the
underlying mechanism and the direction of causality in
this association remain to be elucidated, several groups
have pointed toward HPA axis disruption and immune
activation in cancer-related depression. As often seen in
non-cancer-related major depression, depressed patients
with gynecologic and breast cancer do not suppress cor-
tisol levels after dexamethasone administration [54,55].
Depressed patients with metastatic breast cancer have
shown decreased HPA axis response to awakening, and
both depressed and non-depressed patients in this study
also had a blunted cortisol response to acute stress [56].
In addition, depressed cancer patients display elevated
levels of IL-6 relative to both non-depressed cancer
patients [55,57] and depressed non-cancer patients [57].
In contrast to this inflammatory state, cancer and stress
can also induce immune suppression. Psychological
stress, in patients treated surgically for breast cancer,
can lower natural killer (NK) cell lysis and response to
IFN-γ [58]. As NK cells attack transformed and dying
cells without antigen presentation, they may provide an
important role in cancer surveillance and thus impaired
NK activity is relevant to cancer prognosis [53].
The potential iatrogenic role of cancer treatment to
promote immune dysfunction and subsequent depression
cannot be ignored. IL-2 and IFN-α are commonly used as
cancer treatments and can induce cognitive disturbance,
psychological symptoms, and neurovegetative symptoms of
depression including loss of appetite, fatigue, and altered
sleep [59-61]. Mechanistically, these elevated cytokines may
generate glucocorticoid resistance, perhaps by interfering
with glucocorticoid receptor translocation [62,63], and thus
leading to chronically elevated plasma cortisol associated
with the depressive state. Additionally, elevated cytokines
can downregulate serotonin [64] and promote indoleamine
2,3 dioxygenase activity, which would further reduceserotonin synthesis by promoting a switch in tryptophan
metabolism towards kynurenine and quinolinic acid
[65]. This hints at directionality in the link between
cancer and depression, suggesting that cancer-associated
inflammation promotes neurochemical alterations as-
sociated with depression.
While cancer has on the one hand been proposed to
promote depressive symptoms by altering HPA and
immune function, depression and associated HPA and
immune alterations have, on the other hand, themselves
been put forth as potential modulators of cancer risk
and/or morbidity [53]. Depressed patients are less likely
to adhere to medical therapies [66], which may account
for some reports of worse outcomes in depressed cancer
patients [67]. Sapolsky and Donnelly [68,69] showed
that stress-induced growth of a virally-derived tumor is
accelerated in aged male rats, potentially due to tumor
resistance to glucocorticoid inhibition of glucose transport
[69]. In prostate cancer cell lines, glucocorticoids can
promote androgen-independent growth [70]. Depression
alone has been associated with increased CD4/CD8 ratios,
decreased percentages of lymphocytes including T and B
cells, and decreased circulating NK cells [71,72]. However,
the clinical literature regarding the impact of pre-existing
depression on cancer risk and progression remains divided
and poorly controlled.
Given the sex-specific susceptibility to certain cancer
types, and the bidirectional relationship between cancer
and depression, how then does sex affect cancer-related
depression? Several studies have attempted to answer
this question with mixed results (reviewed in Massie [11]).
In a recent Canadian study with over 10,000 patients at
two major cancer centers, women were twice as likely as
men to report clinical levels of depression as determined
using the Psychosocial Screen for Cancer questionnaire
[73]. Reported depression varied by cancer type, with the
greatest disparity in lung cancer and an absence of a sex
difference in neuroendocrine cancers. However, another
study examining depression rates using the Hospital
Anxiety and Depression Scale in patients with inoperable
small cell and non-small cell lung cancer reported that
rates of depression in the non-small-cell lung cancer
patients differed by sex (31% female vs. 19% male) but not
among the small-cell lung cancer patients (46% female vs.
41% male) [74]. Secondary analyses demonstrated that this
sex difference or lack thereof correlated with prognosis,
such that it existed for the good prognosis patients
(with women reporting higher depression) but disappeared
among the poor prognosis patients [75]. Miller and
colleagues [76] reported a similar finding among patients
with stage III or stage IV lung or stage IV gastrointestinal
cancer (including colon rectum, pancreas, appendix, and
hepatobiliary cancers), using the Beck Depression Inventory
II to assess depression. In this study, there were no
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depressive symptom severity [76]. In another study focusing
on the role of fatigue, pain, and/or depression in predicting
quality of life (QoL) in patients with varying cancer
types, women had lower scores for quality of life in the
Multidimensional QoL Scale-Cancer and reported greater
pain, but equal depressive symptoms on the Center for
Epidemiological Studies –Depression Scale [77]. Pain and
depression predicted female QoL, while depression alone
predicted male QoL, indicating depression as an important
factor for both male and female cancer patients. Of course,
it is critical to remember that the tools used to assess
depression in these studies vary widely, and may account
for some disparities seen, making between-study compari-
sons difficult. However, the trend across assessment tools
for a relative leveling of the susceptibility to depression in
severe cancer cases seems consistent.
The mechanisms underlying this alteration in sex-specific
vulnerability to depression in cancer remain unclear.
Some studies have reported increased depression in
women associated with estrogen deficiency due to tamoxi-
fen, an estrogen receptor antagonist, or other chemothera-
peutic treatment [78,79]. In contrast, one larger study of
tamoxifen treatment vs. placebo in non-cancer patients did
not find any statistical difference in rates of depression
[80,81]. It is however possible that the combination of the
cancer stressor combined with the estrogen deficiency may
be necessary for induction of the depressive state.
Cardiovascular disease, sex, and depression
Aging positively correlates to the incidence and prevalence
of cardiovascular-related disease, as age remains one of the
greatest risk factors for the emergence of the disease in
both men and women [82,83]. Women, however, begin to
outnumber men in cardiovascular disease prevalence
starting around age 45, and cardiovascular disease is the
leading killer of women over the age of 50 [82,84]. Similar
to other disease states, the change in demographics of
cardiovascular disease and the increased burden on women
is attributed to the negative pathologic consequences
(loss of antioxidant, anti-inflammatory, and neuroprotective
properties) associated with the cessation of ovarian
function [85,86].
The manifestation of depression occurs in approximately
15-20% of patients with cardiovascular diseases, a rate
three times what is observed in the general population
[12] (see Table 1). The links between depression and
cardiovascular disease are strong; with evidence supporting
the bidirectionality of onset. Low heart rate variability,
an indicator of poor autonomic control (i.e. inflexibility),
among depressed patients is associated with dramatic
effects on vascular function, including increased peripheral
resistance, arterial hypertension, and organ damage [87,88].
Depressive events are reported to precede cardiovascularevents, and the manifestation of depressive episodes
early in life confers a greater risk of the development of
cardiovascular disease [4,87]. Similarly, cellular mechanisms
associated with mood disorders and stress give rise to
vascular damage observed in cardiovascular diseases while
the co-expression of the two disease states is associated
with the greater risk of cardiovascular events as well as a
poorer prognosis following these events [12,87]. Conversely,
depression is a common consequence of stroke and other
vascular events, occurring in an estimated one third of
people [89,90]. Furthermore, patients who have suffered a
stroke are at a six-fold greater risk of developing depression
for up to two years following the event [91]. Though
direct causality is still a mystery, vascular-induced changes
to endocrine status [92], neurotransmission [93], and
neuroinflammation [94,95] have all been associated with
the development of depression.
The linkage of cardiovascular disease to depression,
especially late-life depression, is thought to be the product
of reduced blood flow [96]. The hippocampus and frontal
cortices are susceptible to reduced blood flow and have
been shown to exhibit reduced blood flow in depressed
patients [97-99]. Moreover, in addition to proposed
reduced blood flow, white matter hyperintensities, a sign
of hypertension [100], are evident in depression, especially
in old age [101,102], and appear to positively correlate
with the progress of depressive symptoms [103]. Further,
the locations of the white matter intensities correlate with
some aspects of the scope of the depressive disorder,
though this remains controversial. For instance, when
white matter intensities are evident in subcortical areas, a
greater percentage of anger attacks are reported in those
depressed persons [104]. Similarly, when gray matter
hyperintensities have been examined, an apparent positive
correlation exists between the presence of those abnormal
signals in the basal ganglia and suicide attempts [105],
although that study was 85% populated by women.
Sex steroids influence the onset of depressive symptoms
as well as the susceptibility to cardiovascular events; how-
ever, the interaction of the two disease states is unclear.
Though the overall rates of depression are greater among
patients with cardiovascular disease, women are still at a
double risk of developing depression, a rate that is consist-
ent with what is observed in the general population [12].
Beginning at menopause, a woman’s risk for cardiovascular
diseases increases as a result of decreased estrogen activity
and parallels a decreased risk for depressive disorders
[82,86]. These data suggest that hormonal status can influ-
ence mood and cardiovascular disease independently, even
when co-expressed. Because men have higher circulating
levels of androgens for a greater proportion of their lives,
high levels of androgens have often been associated with
the development of cardiovascular disease and implicated
in the earlier onset of the condition in men relative to
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testosterone are typically lower in men with cardiovascular
disease compared to an age-matched healthy population
suggesting either an alternative mechanism or a dynamic
role for testosterone [82,86]. Furthermore, low levels of
total and bioavailable testosterone in men are associated
with depressed mood, although data on the topic are
controversial [86,106,107]. The role androgens play in
depressive behaviors and cardiovascular disease in men
is less clear, and the coexpression of the two disease
states does little to elucidate the relationship. In men,
other factors may weigh more heavily than androgen
status for the emergence of cardiovascular disorders,
such as cholesterol [85] and alterations to the HPA axis
[84], which both are implicated in depressive disorders
[108,109]. Together, these data and others suggest that
there is a biological basis of sex-influenced vulnerability
for depressive symptoms through a cardiovascular
mechanism and that such clinical and preclinical studies
should be explored.
Conclusions
In conclusion, we assert that not all depression is created
equal. The evidence presented here indicates that sex
interacts with disease to precipitate depression whether
the disease is neural (as in epilepsy and AD) or somatic
(e.g., cancer and cardiovascular disease) in origin. The
relationships described in this review highlight the
complex disease-depression interaction as well as the
multitude of factors that influence the expression and
severity of each condition. In each of the diseases
discussed herein, the prevalence of comordbid mood
disorders is much higher than in the general population
(see Table 1), though in each case the direction of causality
is unclear. It appears as though the directionality of the
depression-disease relationship is two-fold, such that each
state lowers the threshold for the other, depending on the
genetic and environmental susceptibilities of each.
The typical 2:1 female predominance in the presentation
of mood disorders is tempered in at least some comorbid
disease states. Baseline changes in neurochemical signaling
due to the disease state, as in epilepsy [32], altered neuro-
biology secondary to inflammatory mechanisms associated
with disease, as in cancer [53,59], or a combination of these
factors seem to interact with sex to alter vulnerability to
mood disorders. The exact role of sex steroids and whether
fluctuations (eg. androgens in cardiovascular disease and
estrogen in AD) or absolute levels of hormone may miti-
gate some degree of disease progression and susceptibility
to depression remains unclear. A review by Cahill [110] of
“His brain, her brain” similarly addresses the neurobiology
of sex differences in disease and advocates for appropriate
treatment in light of these differences. Indeed differential
coping styles of men and women [111] may contribute atleast in part to depressive symptoms; however, several
studies have cited not only the bidirectional nature of
depression and disease [14,53,87], but the biological
basis for depression within disease [95,112,113].
The precise systems that are dysregulated in the
manifestation of depression likely vary by the root
cause of the disorder. The originating biological cause
of depression will depend on the sex, age, and disease
state of the individual. For instance, the point of origin
is likely to vary substantially between a healthy adolescent
girl abused as a child, an adult woman with epilepsy, and
an elderly man with cardiovascular disease and a history of
cerebral ischemia. Once it is understood that depression is
not a singular disorder but rather a common phenotype
for a variety of underlying biological disruptions, both
central and peripheral in origin, preclinical research
will be better designed to identify and target potential
therapeutic mechanisms, leading to more specific and
effective clinical treatments.
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